RxDoctor Payments Data

Mir Madani, MD

Critical Care Medicine · Los Alamitos, CANPI 1982611760

Payments from drug & device makers

$8,399in general payments, 2019–2025

Across 389 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$1K
  • Pfizer$691
  • Bayer$647
  • Lilly USA, LLC$557
  • Boehringer Ingelheim$497
  • plus $4K from 30 others

What the payments were for

  • Food & beverage$8,399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,399 in reported general payments places this provider in the 85th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$437,705
Medicare patients
641
Services billed
3,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$102,996
EliquisApixaban86$81,166
JardianceEmpagliflozin46$62,577
FarxigaDapagliflozin Propanediol52$49,049
RybelsusSemaglutide19$32,999
Trijardy XrEmpaglifloz/Linaglip/Metformin15$25,459
MounjaroTirzepatide16$23,069
JanuviaSitagliptin Phosphate19$23,067
XareltoRivaroxaban16$23,053
ElmironPentosan Polysulfate Sodium11$10,857
EntrestoSacubitril/Valsartan18$9,193
Repatha SyringeEvolocumab11$5,783
Dexlansoprazole DrDexlansoprazole16$5,707
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,413
Celecoxib34$4,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$51$135,99592 claims
Boehringer IngelheimJardiance, Trijardy Xr$497$88,03661 claims
PfizerEliquis$691$81,16686 claims
AstraZenecaFarxiga$335$49,04952 claims
Lilly USA, LLCMounjaro$557$23,06916 claims
MerckJanuvia$260$23,06719 claims
Johnson & JohnsonXarelto$1,011$23,05316 claims
NovartisEntresto$1,022$9,19318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →